Oncologist serving people w/ #cancer in #MedEd#SciComm & #bcsm. Past ASCO Ed Chair. Cofounder @HCWvsHunger. #LongCovid. Team hope/good trouble/go high. No FCOI
My grandpa used to say “It’s not what you know, it’s who you know.” The 1st time I was old enough to get it, I said “That’s not fair!” He said “Exactly! So make it your life’s work to ensure everyone meets each other.” He’s 2 decades gone, but I’m still at it. #advocacy#MedEd
Dr. Tim Henrich presented new findings surrounding long term persistence of SARS-CoV-2 proteins & RNA in Long COVID gut tissue at PolyBio’s recent Spring symposium. “We actually see [gut viral persistence] in both areas, the epithelium—which turns over every several days to week—to the lamina propria where you have long-lived myeloid immune cells… suggesting there may even be replication in some individuals,” said Henrich.
Using a highly sensitive method of detecting viral RNA, “around 20-25% of the time, we see detection… all the way up until 3-4 years after initial infection” in Long COVID patients.
Food insecurity is not just a social issue — it is a cancer outcomes issue‼️
Pts with MBC living in food deserts had distinct genomic profiles, including higher rates of RTK/RAS pathway alterations and CCNE1 copy number variants, along w/ worse survival outcomes — particularly among Black pts.
A powerful reminder that biology and structural inequities are deeply intertwined.
#HealthEquity #ASCO2026 @OncoAlert
Fresh off of #ASCO26, I'm compelled to share more about how NCI-funded research fuels progress. Our #YourNCI initiative describes how @theNCI—through critical funding and hands-on science across the cancer continuum—advances research, leading to better outcomes for patients.
#DB05 update on #ILD with T-DXd
10% ILD 🫁 , 2 cases fatal
Radiation pneumonitis ☢️ (RP) incidence ~ 30%
Having ILD did not ⬆️ chance of RP
📌No diff in ILD 🫁 based on sequential or concurrent radiotherapy ☢️
Moderate renal dysfunction ⬆️ risk ILD
#ASCO26
@ScaltritiLab I’ll always remember with joy and wonder the standing ovation at ASCO ‘05 for adjuvant Herceptin. (I was a fellow, and that was the 2nd time I had ever attended an ASCO Annual Mtg!)
New JAMA Network Open study:
📊 Long COVID prevalence estimated at ~16%
🏥 58 U.S. hospitals
🤖 AI-based EHR phenotyping
⚠️ Diagnosis codes alone missed many cases
The burden of #LongCOVID is likely much larger than initial data suggest.
https://t.co/uqyJoejzDb
Excited to share our study by @keylas3 et al. on pathological autoantibodies in people with Long COVID. We asked whether IgG in patients with Long COVID bind to human tissues/antigens and cause pathologies when transferred into mice. With @PutrinoLab
https://t.co/tcowCufWyf
Researchers estimate long COVID could cost the US more than $8 billion by 2027.
At least 44 million Americans have reported symptoms, with lost work productivity driving over 90% of the economic burden.
https://t.co/ttnp6kwqGn
'STORM' is a short documentary about Scott Hugo. A story of Long COVID's impact on his life and family - a reminder of what is at stake in research on Long COVID.
His resilience humbles me.
Please watch and share 🙏🏼
https://t.co/tN7B5wcq2I
I am not loving this trend of AI generated infographic explanation of pivotal clinical trial data. Many of them are straight up wrong as they aren’t peer reviewed or even created by an expert in that cancer type. Be CAREFUL when using these to learn about data and look at the source. #bcsm #breastcancer
11:10 am ET—Resia Pretorius discussed several new papers that help establish the process of microclot formation in Long COVID & Post-Vaccination Syndrome. One study demonstrated variable proteomic clotting-related signatures between LC & PVS, including inverted PF4 & S100-A9 levels between the conditions.
📣 Four new #breastcancer#FDA approvals in the first 3 wks of May!
#OncTwitter#MedTwitter, if you need ONE central place with concise info on cancer drug approvals, share & bookmark this site: https://t.co/6K1E3FhPlM.
#Regulatory#MedEd
Excited to share our latest paper, out today @CellCellPress. We found that large pieces of the human genome can transfer between cells upon direct contact, endowing recipient cells with heritable phenotypic changes. (1/7)
https://t.co/SbshGhofN0
@DrHBurstein Pertuzumab was approved (accelerated approval) in 2013 for neoadjuvant, on the day that APHINITY completed accrual. Later granted regular approval in
2017 after APHINITY results were available. #bcsm
May is #SkinCancer Awareness Month, so I’m resharing my thread about #melanoma honoring the late President Jimmy Carter. Learn more & to find out where to get a free skin cancer screening if you need one. #melsm#MedTwitter#OncTwitter
cc @CarterCenter
President Jimmy Carter died today at age 100, having lived w/ melanoma that had spread to his brain & liver for >9y. I grew up in GA admiring him, so as an oncologist, I’d like to honor his life by teaching you a bit. #melsm#MedTwitter
First, the ⚠️ signs (ABCDE 👇) & pics
/1
Wow- big month for breast approvals so far...and it's only May 15th!
#TDXd approved for neoadjuvant and adjuvant HER-2+ #bcsm
Our @US_FDA breast colleagues have been very busy, thank you!
@drsarahsam@scserendipity1 Congrats! Good to know you’ll be there, along with one of my favorite breast onc fellows at Hopkins Kimmel, Maddie Klugman. (My husband @gleeson_md is also at UMD & at the Balt VA Hosp in ID, but hope you guys never need him for your onc patients. 😊)